Home ›
Sarcoma Trials ›
NCT06367075
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
This is a single-arm, multicenter trial of cadonilimab (AK104) with adriamycin in patients with first-line advanced soft tissue sarcoma. the primary objective is to evaluate objective response rate of cadonilimab with adriamycin.
Trial Details
NCT ID NCT06367075
Phase PHASE2
Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status RECRUITING
Cancer Type Sarcoma
Interventions
Locations (sample) Wuhan, Hubei, China|30.58333,114.26667
Key Eligibility Criteria
Patients who were pathologically confirmed soft tissue sarcoma (soft tissue sarcomas other than alveolar/embryonal rhabdomyosarcoma, clear cell sar… The patient was diagnosed as progressive and the investigators determined that the lesion was not suitable for surgical treatment The patients had not received systemic therapy (including chemotherapy, targeted therapy and bioimmunotherapy) for advanced soft tissue sarcoma. Mo… In patients with measurable disease, lesions are defined and monitored by RECIST v1.1
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →